As a clinical entity, myasthenia gravis was not recognized until Samuel Wilks in 1877 described bulbar and peripheral muscular weakness and was struck by the absence of pathology in the central nervous system [1] . However, the earlier, controversial description by Thomas Willis [2] (ignored by Osler) is a convincing clinical account [3] .
The German physicians Erb in 1879 and Goldfl am in 1893 later reported new and detailed expositions, though Erb, a pioneer of electrodiagnosis, failed to record the myasthenic decrement in response to faradic stimulation. Jolly, in 1895, wrote:
'When muscles are stimulated repeatedly by Faradism a reaction of asthenia is demonstrated, yet when the muscle no longer responds, it will respond immedi-gr. 1/60 produced no obvious effect, but an hour after gr. 1/30 slight improvement occurred.' No improvement followed control injections of water, pilocarpine, strychnine, adrenaline, ephedrine or acetylcholine.
'I think that this effect of physostigmine on myasthenia gravis is important, though it is only temporary, for it improves swallowing and might tide the patient over a respiratory crisis. It supports the opinion that fatigability is due to poisoning of the motor end-organs, or ''myoneural junctions'' … I am, Sir, yours faithfully, M.B. Walker. St. Alfege's Hospital Greenwich, May 12th [1935] .' Physostigmine had to be given by injection and had unpleasant side-effects and so Walker tried oral prostigmine (Roche). In 1935, a 'Miss C.' became the fi rst person given oral prostigmine (neostigmine) for myasthenia gravis. A myasthenic since February 1928, she had failed to benefi t from several hospital admissions. She was transferred to St. Alfege's Hospital on October 24, 1934 and given hypodermic prostigmine 2.5 mg and atropine 1/100 g three times daily with an excellent response.
However, the report of the benefi cial effect was greeted with general skepticism because the relief of myasthenic weakness was brief. In 1938 when her discovery was formally demonstrated to the Royal Society of Medicine and others had confi rmed the benefi ts, general acceptance supervened. She described her detailed observations and experiments in her MD thesis (Edinburgh University in 1935) for which she was rewarded with a gold medal. Mary Walker had made one of those few therapeutic discoveries for a specifi c disorder, like fi nding the key for a locked gate.
She also described a clinical sign in myasthenia known as 'the Mary Walker effect': the myasthenic patient vigorously exercises the forearm with a tourniquet applied at the elbow infl ated to 200 mm Hg; the tourniquet is released when the patient tires and partial ptosis develops a few minutes later. The humoral mechanism responsible remains open to speculation [7] .
Mary Broadfoot Walker ( fi g. 1 ) was born at Croft-anRigh, Wigtown, Scotland. After school, she entered the medical school with all the customary diffi culties then imposed on women. In 1913, she graduated MB, ChB from Glasgow and Edinburgh Medical College for Women. In World War I, she joined the Royal Army Medical Corps and served at the 63rd General Hospital, Malta. After the war, in 1920, she became Assistant Medical Offi cer in 'Poor Law Service' at St. Alfege's Hospital, Greenwich. Against formidable competition at the time in 1932, she passed the London Membership of the Royal College of Physicians. It was 2 years later that she revealed her fi ndings in myasthenia gravis in the work which formed the substance of her 1935 MD thesis.
It is hard to imagine now the diffi culties faced by women doctors in Britain during the early 20th century. Dr. Treatment of myasthenia was not her only discovery, for with few resources, she was possibly the fi rst to demonstrate that familial periodic paralysis was associated with hypokalaemia [8, 9] . The title of this 1935 paper is misleading and probably refl ects the confusion at that time about the nosology of myasthenia gravis, periodic paralysis and the role of defects in potassium metabolism.
In 1954, she retired to Croft-an-Righ, her father's home, originally built as a hunting lodge for Scottish Kings. 'Local people remember her tenure of the house as one fi lled with laughter and cats and stories about the walnut tree in her garden.' But ever zealous, she also continued to work at Glasgow Royal Maternity and Women's Hospital. Her interest in myasthenia continued as shown by the letter Fig. 1 Sir Henry Dale's Nobel-Prize-winning work (1934) showed acetylcholine as a neurotransmitter at the myoneural junction. Research later showed that 3/4 of patients with generalized myasthenia and half with ocular myasthenia had serum acetylcholine receptor antibodies and in cases with thymomas, CD4+ and CD8+ T cells were generated [13] .
In 1960, J. A. Simpson suggested that myasthenia gravis 'is an ''auto-immune'' response of muscle in which an antibody to end-plate protein may be formed' [14] . Osserman and Genkins [15] confi rmed the role of an autoimmune genesis and established a classifi cation. Current immunosuppressive treatments are based on these investigations.
